Download 09 - 2012 Emerging Medical Technologies Spotlight: A Report of... Partnering Opportunities

Brochure
More information from http://www.researchandmarkets.com/reports/2298249/
09 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment &
Partnering Opportunities
Description:
This report includes details on 30 emerging medical technology companies that have been identified by LSI's
in-house research team in September 2012.
All companies include technology, market(s), key executive, and contact information.
Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies
This report may be purchased separately or as part of LSI's Emerging Medical Technologies Spotlight Library.
Contents:
BRIEF TECHNOLOGY DESCRIPTIONS FOR COMPANIES COVERED
- 1-Automated robotic delivery system that can securely transport one patient's prescription or an entire
unit's scheduled doses on-demand from the pharmacy to the nurses' station and 2-A web-based medication
tracking system that uses a combination of passive RFID, barcodes, biometrics, remote monitoring, and/or
secure delivery carts to keep the pharmacy in touch with all orders, while meeting all compliance regulations
- Strip-based diagnostic test that will quickly and cost-effectively provide a definitive determination of
whether a patient has suffered a cerebrospinal fluid leak as a result of surgery or trauma
- Small molecule that increases the natural production of erythropoietin (EPO) and causes a controlled,
gradual rise in hemoglobin in patients with anemia
- Low-cost, high-value terpenes as therapeutics for infectious & cardiovascular diseases, oncology, and
metabolic disorders
- Proteomics-based biomarker discovery that leads to superior data, better results, and improved
diagnostics
- Tests that measure and analyze important genomic variants affecting the metabolism and response to
behavioral health medications in individual patients
- Non-invasive, continuous monitor for the early detection of cerebral fluid accumulation due to stroke,
traumatic brain injury (TBI), or brain surgery
- Formulation platform technology that provides tamper-resistant extended release drug delivery, for the
treatment of chronic pain
- Interatrial Septal Device (IASD) for the treatment of congestive heart failure (CHF)
- Molecular diagnostic tests to target rare forms of cancer, including pediatric cancers
- Next-generation synthetic bone graft substitutes with optimized handling, reliability, and consistent
surgical performance; for use in a broad range of non-load bearing osseous repair defects
- Implantable, programmable pump designed to deliver therapeutic drugs into the spine, for the treatment
of chronic intractable pain and the management of severe spasticity
- Device for the treatment of chronic cardiovascular disease
- Externally delivered ultrasound energy to ablate the renal nerves, as a non-invasive, single-treatment, nonpharmacological approach to control hypertension
- Adeno-associated virus (AAV) delivered follistatin protein that is safer and more targeted, to increase
muscle strength and improve the quality of life of muscular dystrophy patients
- 1-Tests for preimplantation genetic diagnosis (PGD) performed during in-vitro fertilization in order to select
embryos with the highest probability of becoming healthy children; 2-Conception testing following
miscarriage in order to understand the cause; and 3-Non-invasive prenatal testing to determine paternity or
detect genetic disease
- New class of pentraxin therapeutics to treat rare fibrotic diseases, including: idiopathic pulmonary fibrosis
(IPF), myelofibrosis, and fibrovascular retinal diseases
- Technology that works by measuring and analyzing the light reflected off of the skin to make an accurate
pressure ulcer (PU) diagnosis regardless of skin color and independent of the clinician's skill level
- Compounds that possess a low risk of side effects, for central nervous system (CNS) disorders, including:
schizophrenia, major depressive disorder (MDD), pain, traumatic brain injury (TBI), multiple sclerosis (MS),
autism (Fragile X), anesthesia, and post-traumatic stress disorder (PTSD)
- Suture delivery device that has the potential to transform certain open surgical procedures, traditionally
performed in the operating room, into more cost-effective procedures that can be performed in the
catheterization lab, where only a small piece of suture is left behind
- Molecular diagnostic assays that will enable new paradigms in the treatment of diseases as diverse as
infection, auto-immune disease, and cancer
- Disruptive technology with the potential to transform the standard of care for root canal procedures
- Small molecule drug candidates that modulate the sphingosine 1-phosphate (S1P) pathway in new and
different ways, for the treatment of diseases such as cancer and fibrosis
- Highly selective qPCR reagents that provide an increased level of confidence and convenience for the
detection of key cancer mutations
- Sustained release drugs for treating tardive dyskinesia (TD) and other movement disorders
- Platform for surgery to be performed through a patient's mouth or other natural orifices, rather than the
abdomen, for less pain, shorter hospital stays, reduced risk of wound infection, and no external scars
- Ultrasound system, specifically for patients with dense breast tissue, where the effectiveness of
mammography may be limited
- Unique retractable over-the-wire guidance system to assist in optimal atraumatic intravenous catheter
delivery, designed for greater first attempt success and increased dwell times
- Innovative platform for the rapid generation of monoclonal antibody therapeutics for the treatment cancer
and age-related macular degeneration (AMD)
- Physiological and biomechanical monitoring technology that enables loved ones to stay in their home
longer while family, friends, and medical practitioners can remotely monitor their physiological state
Ordering:
Order Online - http://www.researchandmarkets.com/reports/2298249/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
09 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment &
Partnering Opportunities
Web Address:
http://www.researchandmarkets.com/reports/2298249/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Single User:
USD 199
Electronic (PDF) Enterprisewide:
USD 1195
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World